Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lincomycin + lidocaine gel is a topical combination pharmaceutical product developed by Henan Lingrui Pharmaceutical, primarily marketed in China. It contains two active small molecule ingredients: lincomycin hydrochloride (5 mg/g) and lidocaine hydrochloride (4 mg/g). Lincomycin is a lincosamide antibiotic that exerts its antibacterial effect by binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis. Lidocaine is a local anesthetic that works by blocking voltage-gated sodium channels, preventing the initiation and conduction of nerve impulses to provide rapid pain relief. The product is formulated as a green, transparent aqueous gel and is indicated for the treatment of mild burns, trauma, and mosquito bites complicated by bacterial skin infections, providing simultaneous anti-infective, analgesic, and anti-pruritic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lincomycin + lidocaine gel.